Iterum Therapeutics at the Maxim Healthcare Virtual Summit
Iterum Therapeutics plc (ITRM) is gearing up to participate in the very important Maxim Healthcare Virtual Summit. This clinical-stage pharmaceutical company is renowned for its focus on developing next-generation oral antibiotics designed to tackle infections that arise from multi-drug resistant bacteria, particularly in community settings. Corey Fishman, the CEO of Iterum, is set to have an engaging Fireside Chat with Jason McCarthy, Ph.D., a well-respected figure in biotechnology research at Maxim Group. This chat will take place at 10:00 a.m. ET.
Details on the Summit
The Maxim Healthcare Summit is scheduled to run from October 15 to 17, featuring a dynamic array of discussions related to the healthcare industry. Attendees will gain insights into key topics affecting the market, along with the latest developments in the treatment of infectious diseases. Thanks to M-Vest, the conversations will be accessible online, allowing for extensive participation and viewership.
About Iterum Therapeutics
Iterum Therapeutics is dedicated to advancing its mission of addressing the urgent global crisis posed by multi-drug resistant pathogens. The company is devoted to enhancing the quality of life for those afflicted by serious health issues globally. Iterum's most promising product, sulopenem, represents a novel approach as a penem anti-infective compound, available in both oral and IV forms. This compound boasts impressive in vitro activity against a spectrum of bacteria, including numerous gram-negative and gram-positive strains resistant to various antibiotics.
Regulatory Advancements
One of the significant milestones for Iterum Therapeutics includes the submission of a New Drug Application (NDA) for oral sulopenem aimed at treating uncomplicated urinary tract infections in adult women. The U.S. Food and Drug Administration has accepted this NDA for review. This process highlights the importance of Iterum's work in the field, which has also garnered Qualified Infectious Disease Product (QIDP) and Fast Track designations for several uses of sulopenem.
Contact Information for Investors
For investors interested in the latest developments or potential opportunities with Iterum Therapeutics, they can reach out to Judy Matthews, the Chief Financial Officer, at 312-778-6073. Investors can also connect via email at IR@iterumtx.com.
Frequently Asked Questions
What is the focus of Iterum Therapeutics?
Iterum Therapeutics focuses on developing novel antibiotics to combat multi-drug resistant infections.
When will the Maxim Healthcare Virtual Summit take place?
The summit is scheduled from October 15 – 17, 2024.
Who will be featured in the Fireside Chat?
The Fireside Chat will feature Corey Fishman and Dr. Jason McCarthy discussing critical issues in biotechnology.
What is the significance of sulopenem?
Sulopenem is potential treatment for common urinary tract infections, offering a new option against resistant bacteria.
How can investors learn more about Iterum?
Investors can reach out to the company through their Investor Relations contact or visit their website for updates.